Sangui Biotech International Inc (SBH) - Total Liabilities
Based on the latest financial reports, Sangui Biotech International Inc (SBH) has total liabilities worth €1.10 Million EUR as of March 2023. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Sangui Biotech International Inc - Total Liabilities Trend (2014–2022)
This chart illustrates how Sangui Biotech International Inc's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Sangui Biotech International Inc Competitors by Total Liabilities
The table below lists competitors of Sangui Biotech International Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
TPXimpact Holdings plc
LSE:TPX
|
UK | GBX17.56 Million |
|
Remington Resources Inc
V:RGM-H
|
Canada | CA$1.04 Million |
|
Clean Power Hydrogen PLC
LSE:CPH2
|
UK | GBX3.05 Million |
|
GCL Global Holdings Ltd Warrants
NASDAQ:GCLWW
|
USA | $123.85 Million |
|
Lion Group Holding Ltd
NASDAQ:LGHL
|
USA | $42.46 Million |
|
Guess? Inc.
NYSE:GES
|
USA | $2.44 Billion |
|
Metgasco Ltd
AU:MEL
|
Australia | AU$12.35 Million |
Liability Composition Analysis (2014–2022)
This chart breaks down Sangui Biotech International Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.04 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -3.10 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 12.33 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Sangui Biotech International Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Sangui Biotech International Inc (2014–2022)
The table below shows the annual total liabilities of Sangui Biotech International Inc from 2014 to 2022.
| Year | Total Liabilities | Change |
|---|---|---|
| 2022-06-30 | €1.03 Million | +1.61% |
| 2021-06-30 | €1.01 Million | +18.04% |
| 2020-06-30 | €855.21K | +27.46% |
| 2019-06-30 | €670.96K | +48.06% |
| 2018-06-30 | €453.17K | +27.91% |
| 2017-06-30 | €354.30K | -1.03% |
| 2016-06-30 | €357.99K | -22.50% |
| 2015-06-30 | €461.93K | +82.36% |
| 2014-06-30 | €253.31K | -- |
About Sangui Biotech International Inc
Sangui Biotech International, Inc., through its subsidiaries, engages in the manufacturing and sales of wound treatment and cosmetic products. The company offers artificial oxygen carriers comprising oxygen carrying blood additives and oxygen carrying blood volume substitutes; nano formulations for the regeneration of skin; chitoskin wound pads; Hemospray, a hemoglobin based wound spray; and woun… Read more